Today
Crescent launches $43m block trade in ClearView Wealth
Stockbroker Morgans Financial was seeking buyers at 59¢ a share or a 1.7 per cent discount to the last traded price.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Yesterday
Fundies have Regis Healthcare founder’s stake on their watch lists
The market has a close eye on founding director Bryan Dorman’s stake in the $1.2 billion aged care provider.
- Sarah Thompson, Kanika Sood and Emma Rapaport
This Month
Brookfield’s Healthscope debt trap is a mess for everyone involved
The investment giant is bringing its punchy approach to restructuring – and tactics more often found in the US – to Australia as it works on the hospital group.
- Jemima Whyte
Concussion medtech start-up kicks off raise for US expansion
Headsafe hoping to break into the United States healthcare market with its NuroCHEK device, hitting up early-stage investors for $5 million.
- Sarah Thompson, Kanika Sood and Emma Rapaport
G8 Education board faces investor scepticism over Star links
The biggest for-profit operator of childcare also revealed some problems had struck a controversial deal to offload underperforming centres.
- Liam Walsh
New deal! Five V Capital are creatures of Habit
Allied health providers have proved popular – and profitable – for a number of investors, including Quadrant Private Equity, Next Capital and Adamantem Capital.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Menopause hormone therapy is OK after all, long-term study finds
Since a study in 2002 was called off, women have been reluctant to take hormones. But a new study has reassuring news for women under 60.
- Marlene Cimons
Peloton crashes to record low as CEO quits amid lay-offs
The interactive exercise bike company was a pandemic superstar but is now struggling heavily and laying off 15 per cent of the workforce.
- Mark Gurman
April
- Opinion
- Chanticleer
How Chemist Warehouse can get its deal past the ACCC
Divestments may be needed to get the Chemist Warehouse/Sigma deal over the line, but they don’t look too strenuous.
- Updated
- Anthony Macdonald
Healthscope in $919m writedown as hospital costs jump
One of Australia’s biggest private hospital operators plunged into the red as wage and medical supplies costs climbed, and it booked a big impairment.
- Simon Evans
SA’s Benson Radiology orders adviser beauty parade
Sources said Benson is making about $30 million EBITDA a year.
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Opinion
- Chanticleer
How under the radar I-MED is fighting fit after 20-year PE job
Tucked away in private equity, it is easy to forget about Australia’s biggest imaging company I-MED. But it is worth watching this year; it has a few ideas on the boil.
- Anthony Macdonald
- Opinion
- Chanticleer
Adieu: Ramsay Health Care’s shrinking global ambition
Under-pressure Ramsay Health Care is taking a fresh look at its footprint, which could mean a major change in its strategy. Watch this space.
- Anthony Macdonald
- Opinion
- Chanticleer
Private equity back to clean up its mess at troubled jobs agency
Jobs agency APM’s situation gets more bizarre as it goes looking for another frog to kiss.
- Anthony Macdonald
Andrew Thorburn lands CEO role at HammondCare
At his new job, the one-time NAB CEO’s Christianity is unlikely to be an issue.
- Myriam Robin
- Opinion
- Chanticleer
Ansell shows how to create new interest in an old story
Cheap stock never goes out of fashion. The key for a company is to issue it only occasionally, and make the most of when it does.
- Anthony Macdonald
Medtech Atmo Biosciences shop raise at $55m valuation
Alium Capital Management, Japanese pharmaceuticals giant Otsuka Pharmaceutical and Breakthrough Victoria are set to cornerstone Atmo Biosciences $15 million equity raise.
- Sarah Thompson, Kanika Sood and Emma Rapaport
March
- Opinion
- Chanticleer
Can a vaccine slow down the Cochlear train?
Cochlear is firing for investors, but you have to wonder whether everyone’s getting a bit carried away.
- Anthony Macdonald
Healius in management shake-up after CEO exit
Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.
- Simon Evans
Private equity group CVC walks away from $1.83b APM bid
Rich Lister Megan Wynne built APM from scratch in 1994 into a large player generating fees from helping people find jobs, and has expanded as an NDIS provider.
- Simon Evans
